Company intelligence / Profile preview
Zelgen
Kunshan, Jiangsu Province, Chinazelgen.com ↗
- Ownership
- Private
- Employees
- ~867
- Development stage
- Other
01
Overview
Zelgen has a robust pipeline with several commercialized or near-commercial-stage products. Notably, donafenib tosylate is approved for liver cancer; recombinant human thrombin is approved for hemorrhage; jaktinib hydrochloride is at NDA/BLA stage for autoimmune indications such as alopecia areata. The company also has multiple assets in Phase I/II trials targeting oncology and immunology indications
- Therapeutic areas
- DermatologyGastroenterologyHematologyOncologyImmunology
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)Bispecific antibodiesTrispecific antibodiesRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Zelgen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zelgen.